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EDITORIALDigesting GWASnce upon a time, medical genetics was a rela-Otively straightforward business: one gene—one
protein—one disease was sufﬁcient to explain most inheri-
ted disease and was neatly in keeping with Gregor Mendel’s
discovery of alleles with his famous peas. The concept
remains a good starting point but the biology of life is
somewhat more complex, and increasingly we have become
impressed and perplexed, in equal measure, at the striking
variability observed in many inherited conditions, particu-
larly those hitherto believed to be determined by a
heterozygous single-gene mutation or DNA variant, and
therefore following autosomal-dominant inheritance. A good
example is Alagille syndrome, and in this issue of Cellular
and Molecular Gastroenterology and Hepatology, Tsai et al1
proposed a modiﬁer genetic locus to help explain the
great variation in severity of liver disease in this condition.
The authors reached this conclusion by using a technique
that is barely more than 10 years old, namely a genome-wide
association study (GWAS), which is part of the arsenal of
techniques that has heralded the era of genomic medicine.
A GWAS, rather similar to DNA ﬁngerprinting, exploits the
immense variation in DNA sequence between individuals,
these differences consisting of single-nucleotide poly-
morphisms (SNPs), deletions, insertions, and copy number
variations, the majority of which are regarded as essentially
benign. Although a genetic linkage study will set out to
identify the rare single-gene mutations or variants that clearly
cause a particular disease or phenotype, an association study
is potentially useful at ﬁnding common genetic variants with a
relatively weak effect in more complex disorders. A typical
study will adopt a case–control model, comparing 2 cohorts of
subjects, 1 with the phenotype or disorder of interest and the
other functioning as normal controls. It goes without saying
that the criteria for selecting the cohort with the phenotype
should be clinically rigorous whereas the control group
should be as pure as possible (ie, free of contamination from
subjects who might harbor the phenotype). Generally
speaking, the larger the number of subjects in each group, the
better the chances of achieving signiﬁcant results. The
genomes of all subjects then are analyzed for the presence of
at least a million common SNPs, after which the investigation
moves to the statistical phase: are there certain SNPs or alleles
that are seen more often in the disease group compared with
controls, and, if so, by how much (ie, what is the odds ratio?).
This is all well and good, but there are pitfalls and
shortcomings aplenty. Apart from the crucial aspect of
carefully selecting the study cohort by clinical phenotype,
the population background should be taken into account
lest there are common origins with a range of unique but
misleading polymorphisms that give rise to false associa-
tions. The normal variation data accumulating through
many large-scale, biobank-style initiatives and the HumanCellular and Molecular Gastroenterology and Hepatology 2016;2:542–5Variome Project will be vital to the interpretation of results
in many areas of clinical genomics—an issue referred to as
population stratiﬁcation. Ideally, studies should be repro-
ducible in more than one population. Then it must be
appreciated that the results of a GWAS identify a genetic
locus or high-risk SNPs associated with the disease in
question—which is unlikely to be the actual causal gene or
DNA variation. Therefore, beyond the odds ratio, it is of
course pertinent to ask what difference a signiﬁcant asso-
ciation will make to clinical management. Unless further ﬁne
mapping and sequencing work is performed to identify the
speciﬁc gene or DNA variation that causes or modiﬁes the
phenotype, the GWAS statistical results from a study cohort
cannot be meaningfully applied to an individual in a clinical
setting, all of which is highlighted by the study by Tsai et al.1
Perhaps the most fundamental issue is the starting
assumption that a commonmedical condition, or the variability
of a relatively rare genetic disease, has a signiﬁcant genetic basis
that will be uncovered by GWAS. These studies are expensive
and can be criticized on the grounds that few of them have led
to any tangible clinical beneﬁt. However, some have, particu-
larly in relation to identifying the variation in response to
treatment for various diseases, eg, hepatitis C, in which SNPs
close to the interleukin 28B gene determined this variation,2
and the risk of pancreatitis related to treatment of inﬂamma-
tory bowel disease by thiopurine immunosuppressants.3
GWA studies will continue to have a place in researching
genetic variation and susceptibility to disease, although
increasingly will be combined with the next-generation
sequencing strategies of whole-exome and whole-genome
sequencing, the costs of which continue to fall. The hope
and expectation is that these technologies will spearhead
advances that will deliver the much-anticipated era of
personalized medicine. The article by Tsai et al,1 describing
THBS2 as a candidate modiﬁer of liver disease severity in
Alagille syndrome, represents the beginning of a process
that in due course may lead to a change in the way patients
with Alagille syndrome are evaluated and screened.
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